Cytek Aurora Evo flow cytometer

The National Institutes of Health intends to award a Firm-Fixed-Price Purchase Order to Cytek Biosciences, Inc. for the procurement of an upgraded flow cytometry system, specifically the Cytek Aurora Evo flow cytometer. The purpose of this acquisition is to replace the current Cytek Northern Lights system, which lacks sufficient capacity to support ongoing complex clinical trials and patient monitoring. The new system must be compatible with the instrument purchased by the Viral Immunology Section (VIS) to ensure compatibility of reagents, analysis protocols, and interpretation of study endpoints. • The acquisition involves a trade-in of the current Cytek Northern Lights system. • The new system will be used for processing clinical samples for patients with progressive multifocal leukoencephalopathy (PML) and control patient cohorts enrolled in natural history studies and interventional trials. • The system must be compatible with the instrument purchased by the Viral Immunology Section (VIS). • Any available small businesses may submit a written capability statement to demonstrate their ability to perform the requirement.